Home > Newsletters > International Pharmaceutical Regulatory Monitor > EMA Offers Guidance on Marketing Applications for Transdermal Patches
International Pharmaceutical Regulatory Monitor
October 2012 | Vol. 40 No. 10
EMA Offers Guidance on Marketing Applications for Transdermal Patches
Manufacturers of transdermal patches should minimize the amount of residual drug substance in the patch as much as possible to avoid patient and environmental safety risks, according to a new European Medicines Agency (EMA) draft guideline.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.